Switching from Rivastigmine Patch to Oral Formulation
When switching from rivastigmine transdermal patch to oral capsules, use the following dose conversions: patients on the 4.6 mg/24 hours patch should switch to less than 6 mg/day oral (typically 3 mg/day), and patients on the 9.5 mg/24 hours patch should switch to 6-12 mg/day oral (typically starting at 6 mg/day). Apply the first oral dose on the day following removal of the last patch 1.
Dose Conversion Algorithm
The FDA-approved rivastigmine label provides clear guidance for the reverse conversion (oral to patch), which can be applied in reverse for patch-to-oral switches 1:
For patients on 4.6 mg/24 hours patch:
- Switch to oral rivastigmine starting at 1.5 mg twice daily (3 mg/day total)
- This represents the initial oral dosing regimen
- Remove the final patch and begin oral dosing the following day
For patients on 9.5 mg/24 hours patch:
- Switch to oral rivastigmine 3 mg twice daily (6 mg/day total) initially
- Can titrate up to 6 mg twice daily (12 mg/day total) as tolerated
- Remove the final patch and begin oral dosing the following day
For patients on 13.3 mg/24 hours patch:
- Switch to oral rivastigmine 6 mg twice daily (12 mg/day total)
- This represents the maximum oral dose
- Remove the final patch and begin oral dosing the following day
Titration Considerations
After the initial switch, titrate oral doses slowly—increase by 1.5 mg twice daily (3 mg/day total) no more frequently than every 4 weeks 2. This gradual titration minimizes gastrointestinal side effects (nausea, vomiting, diarrhea), which occur significantly more frequently with oral formulations compared to patches 3, 4.
Critical caveat: Oral rivastigmine has substantially higher peak plasma concentrations (Cmax 21.6 ng/ml) compared to the patch (8.7 ng/ml), despite similar overall drug exposure 4. This results in 3-fold higher rates of nausea (23% vs 7%) and vomiting (17% vs 6%) with oral formulations 3, 4. Taking oral rivastigmine with food reduces these gastrointestinal effects 2.
Monitoring After Conversion
Monitor closely for:
- Gastrointestinal symptoms (nausea, vomiting, diarrhea)—most common with oral formulation
- Weight loss—specific concern with rivastigmine 2
- Cognitive and functional status—assess at 6-12 months to ensure maintained therapeutic benefit 2
- Adherence—twice-daily oral dosing may be more challenging than once-daily patch application
Common Pitfalls to Avoid
Do not abruptly discontinue the patch without starting oral therapy. If treatment is interrupted for more than 3 days, restart at the lowest dose (1.5 mg twice daily) and retitrate 1.
Do not assume dose equivalence is exact. The patch provides more consistent drug delivery over 24 hours with less fluctuation, while oral formulations have higher peaks and troughs 4. Some patients may require dose adjustments after switching.
Do not overlook the reason for switching. If the switch is due to skin reactions from the patch, this is appropriate. However, if switching for convenience, recognize that the patch formulation has superior tolerability with similar efficacy 3, 4, 5.